Join us on Tuesday, March 1st as we discuss ——-
“C. diff. Vaccine Update; Sanofi Pasteur’s Cdiffense”
Tuesday, March 1st — Live Broadcast Times
10 a.m. Pacific Time,, 11 a.m. Mountain Time,
12 p.m. Central Time, 1 p.m. Eastern Time
We invite you to listen to the live broadcast and archived programs by clicking on the
Cdiff radio logo displayed below:
This episode we will introduce Sanofi Pasteur, one of the leading vaccine manufacturers in the world, is in the midst of its Phase III clinical trial called Cdiffense to study its investigational vaccine to prevent Clostridium difficile infection (CDI).
The trial is now in more than 20 countries across 5 continents to evaluate the safety, immunogenicity and efficacy of an investigational vaccine for the prevention of primary, symptomatic CDI.
The investigational C. diff vaccine is designed to produce an immune response that targets the toxins generated by C. diff bacteria, which can cause inflammation of the gut. The investigative vaccine ultimately may help prevent a future infection from occurring. Volunteers for the study should be age 50 or older and planning an upcoming hospitalization or have had at least two hospital stays and have received systemic antibiotics in the past year.
For more information on the Cdiffense trial – Please visit www.Cdiffense.org
Dr. Guy de Bruyn, MD – Director for Clinical Development at Sanofi Pasteur, overseeing a large phase III vaccine trial for the prevention of Clostridium difficile infection in some 19 countries on 5 continents around the world that started in the U.S. in 2013.
Dr. Christian Felter, MD – Associate VP, Global Medical Expert for Nosocomial Vaccines for Sanofi Pasteur based in Lyon, France. His focus is on their investigative Clostridium difficile vaccine. Dr. Felter has 11 years of experience in medical affairs roles in the US and Europe, covering therapeutic areas including Immunology, Rheumatology, and Infectious Diseases.
Dr. Patricia J. Freda Pietrobon, PhD – Associate Vice President, Research & Development Sanofi Pasteur Dr. Patricia J. Freda Pietrobon, PhD, Associate Vice President, R&D, Sanofi Pasteur, has over 25 years of experience in the Vaccine & Diagnostic industries and more then 20 years in leadership roles focusing on research & development of new vaccines.
Join us as we introduce Sanofi Pasteur and discuss updates focused on
“C. diff. Vaccine Update; Sanofi Pasteur’s Cdiffense
C. diff. Spores and More™ Global Broadcasting Network – producing educational programs dedicated to C. difficile Infections and more — brought to you by VoiceAmerica and sponsored by Clorox Healthcare
*Please note – The C Diff Foundation does not endorse this product or any product and this posting is strictly for informational purposes only.